3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Melanoma
37
Carcinoma, Non-Small-Cell Lung
10
Thyroid Neoplasms
9
Neoplasms
9
Colorectal Neoplasms
9
Thyroid Carcinoma, Anaplastic
8
Neoplasm Metastasis
6
Multiple Myeloma
5
Glioma
5
Pancreatic Neoplasms
4
Brain Neoplasms
4
Thyroid Cancer, Papillary
3
Recurrence
3
Prostatic Neoplasms
3
Neurofibromatosis 1
3
Lung Neoplasms
3
Hematologic Neoplasms
3
Ameloblastoma
3
Skin Neoplasms
2
Rectal Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neurofibroma, Plexiform
2
Myelodysplastic Syndromes
2
Meningioma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Acute
2
Colonic Neoplasms
2
Breast Neoplasms
2
Astrocytoma
2
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
trametinib
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled